NCT05780034 - A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions

Relapsed/Refractory B-cell Malignancies

Interventions

DRUG

AC676

AC676 will be given orally (PO) on a 28-day cycle.

Trial Locations (9)

RECRUITING

University of North Carolina, Chapel Hill

RECRUITING

Florida Cancer Specialists, Sarasota

WITHDRAWN

Tennessee Oncology, Nashville

RECRUITING

The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

RECRUITING

University of Texas Southwestern Medical Center, Dallas

RECRUITING

Colorado Blood Cancer Institute, Denver

RECRUITING

Oregon Health & Science University, Portland

RECRUITING

Swedish Cancer Institute, Seattle